ADMSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States...

Stats
本日の出来高	3.15M
平均出来高	1.34M
時価総額	0.00
EPS	$-0.430 ( 2021-11-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.189 (2.30%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-24	Mahoney David L	Sell	112 781	Common Stock
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	40 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 2 100 832 \| Sell: 2 425 856

ボリューム相関

長: 0.29 (neutral)

短: 0.76 (moderate)

Signal:(73.528) Neutral

Adamas Pharmaceuticals 相関

10 最も正の相関
SLNO	0.983
BRACU	0.965
XLRN	0.964
LABP	0.962
HCTI	0.961
IMVT	0.959
CYT	0.956
ZYNE	0.951
GTH	0.95
LIQT	0.949

10 最も負の相関
AGZD	-0.992
DXJS	-0.988
UNAM	-0.962
MORF	-0.958
BAFN	-0.945
PEBK	-0.941
AHPI	-0.94
ATSG	-0.94
EDSA	-0.939
PI	-0.939

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Adamas Pharmaceuticals 相関 - 通貨/商品

0.19
( neutral )

0.68
( moderate )

0.60
( weak )

0.48
( neutral )

-0.07
( neutral )

-0.21
( neutral )

Adamas Pharmaceuticals 財務諸表

Annual	2020
収益:	$74.46M
総利益:	$72.42M (97.26 %)
EPS:	$-1.632

FY	2020
収益:	$74.46M
総利益:	$72.42M (97.26 %)
EPS:	$-1.632

FY	2019
収益:	$54.64M
総利益:	$52.17M (95.48 %)
EPS:	$-3.80

FY	2018
収益:	$34.05M
総利益:	$33.41M (98.14 %)
EPS:	$-4.87

Financial Reports:

No articles found.

Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.